Jens-Ulrich Rahfeld

Years Active: 2020-2022
Publications (10 Years): 4

Fraunhofer Institute for Cell Therapy and Immunology

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Fraunhofer Institute for Cell Therapy and Immunology Dec 1o 2013

Germany

Head of Lab Protein Therapeutics :: Department of Molecular Drug Design and Target Validation

Publications

Kathrin Gnoth, Stefanie Geissler, Julia Feldhaus, Nadine Taudte, Victoria Ilse, Sebastian Zürner, Sebastian Greiser, Ulf-Dietrich Braumann, Jens-Ulrich Rahfeld, Holger Cynis, Stephan Schilling
Evidence for Enhanced Efficacy of Passive Immunotherapy against Beta-Amyloid in CD33-Negative 5xFAD Mice. Biomolecules 12 (3) (2022)
Torsten Hoffmann, Jens-Ulrich Rahfeld, Mathias Schenk, Falk Ponath, Koki Makioka, Birgit Hutter-Paier, Inge Lues, Cynthia A Lemere, Stephan Schilling
Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice. International journal of molecular sciences 22 (21) (2021)
Daniel Ramsbeck, Nadine Taudte, Nadine Jänckel, Stefanie Strich, Jens-Ulrich Rahfeld, Mirko Buchholz
Tetrahydroimidazo[4,5- c ]pyridine-Based Inhibitors of Porphyromonas gingivalis Glutaminyl Cyclase. Pharmaceuticals (Basel, Switzerland) 14 (12) (2021)
Kathrin Gnoth, Anke Piechotta, Martin Kleinschmidt, Sandra Konrath, Mathias Schenk, Nadine Taudte, Daniel Ramsbeck, Vera Rieckmann, Stefanie Geissler, Rico Eichentopf, Susan Barendrecht, Maike Hartlage-Rübsamen, Hans-Ulrich Demuth, Steffen Roßner, Holger Cynis, Jens-Ulrich Rahfeld, Stephan Schilling
Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer's disease-like pathology. Alzheimer's research & therapy 12 (1) (2020)

Jens-Ulrich Rahfeld.css-eqlu8i{font-size:small;padding-left:4px;}